SEC
|
TAHL CINDY
|
See Remarks
|
|
-9K
|
$1.06
|
-$9.58K
|
|
SEC
|
Valamehr Bahram
|
President and CEO
|
|
-14K
|
$1.06
|
-$15.33K
|
|
SEC
|
Bressi Jerome Charles
|
See Remarks
|
|
-6K
|
$1.55
|
-$9.27K
|
|
SEC
|
TAHL CINDY
|
See Remarks
|
|
-5.7K
|
$1.55
|
-$8.76K
|
|
SEC
|
Valamehr Bahram
|
President and CEO
|
|
-8.7K
|
$1.54
|
-$13.41K
|
|
SEC
|
Green Jeremy
|
N/A
|
|
+56K
|
$1.68
|
+$94.64K
|
|
SEC
|
Xu Yuan
|
N/A
|
|
-633
|
$4.23
|
-$2.68K
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-2.4K
|
$7.77
|
-$19.01K
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-1.8K
|
$5.00
|
-$9.25K
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-7K
|
$4.37
|
-$30.71K
|
|
SEC
|
TAHL CINDY
|
General Counsel and Secretary
|
|
-11K
|
$4.37
|
-$47.52K
|
|
SEC
|
Valamehr Bahram
|
Chief R&D Officer
|
|
-11K
|
$4.38
|
-$49.37K
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
-14K
|
$4.37
|
-$62.89K
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-5.2K
|
$3.66
|
-$18.97K
|
|
SEC
|
Green Jeremy
|
N/A
|
|
+45K
|
$3.72
|
+$166.02K
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-1.6K
|
$3.50
|
-$5.55K
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-4.7K
|
$2.80
|
-$13.21K
|
|
SEC
|
Xu Yuan
|
N/A
|
|
-632
|
$3.71
|
-$2.34K
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-5.2K
|
$4.83
|
-$25.03K
|
|
SEC
|
Powl Brian T.
|
Chief Commercial Officer
|
|
-3.9K
|
$4.87
|
-$18.77K
|
|
SEC
|
Xu Yuan
|
N/A
|
|
-3.5K
|
$5.58
|
-$19.31K
|
|
SEC
|
Green Jeremy
|
N/A
|
|
+277K
|
$6.17
|
+$1.71M
|
|
SEC
|
Chu Yu-Waye
|
Chief Medical Officer
|
|
-2.5K
|
$6.57
|
-$16.64K
|
|
SEC
|
Green Jeremy
|
N/A
|
|
-277K
|
$5.85
|
-$1.62M
|
|
SEC
|
MENDLEIN JOHN
|
N/A
|
|
+28K
|
$1.37
|
+$38.99K
|
|
SEC
|
MENDLEIN JOHN
|
N/A
|
|
+125K
|
$5.60
|
+$698.20K
|
|
SEC
|
Valamehr Bahram
|
Chief R&D Officer
|
|
+423
|
$1.37
|
+$579.51
|
|
SEC
|
Chu Yu-Waye
|
Chief Medical Officer
|
|
-7.8K
|
$5.24
|
-$41.00K
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-7.3K
|
$5.24
|
-$38.41K
|
|
SEC
|
Plavsic Mark
|
Chief Technical Officer
|
|
-3.4K
|
$5.24
|
-$17.91K
|
|
SEC
|
TAHL CINDY
|
General Counsel and Secretary
|
|
-12K
|
$5.24
|
-$60.54K
|
|
SEC
|
Valamehr Bahram
|
Chief R&D Officer
|
|
-11K
|
$5.24
|
-$57.21K
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
-46K
|
$5.24
|
-$240.55K
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-5.1K
|
$29.81
|
-$153.07K
|
|
SEC
|
Plavsic Mark
|
Chief Technical Officer
|
|
-7.4K
|
$24.61
|
-$183.05K
|
|
SEC
|
Agarwal Shefali
|
N/A
|
|
-841
|
$21.89
|
-$18.41K
|
|
SEC
|
Agarwal Shefali
|
N/A
|
|
-807
|
$22.80
|
-$18.40K
|
|
SEC
|
COUGHLIN TIMOTHY
|
N/A
|
|
-1.4K
|
$22.81
|
-$32.82K
|
|
SEC
|
HERSHBERG ROBERT
|
N/A
|
|
-1.3K
|
$22.75
|
-$30.58K
|
|
SEC
|
Jooss Karin
|
N/A
|
|
-3K
|
$22.82
|
-$67.68K
|
|
SEC
|
MENDLEIN JOHN
|
N/A
|
|
-2.7K
|
$22.79
|
-$62.17K
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
-40K
|
$34.89
|
-$1.40M
|
|
SEC
|
Chu Yu-Waye
|
Chief Medical Officer
|
|
-4.1K
|
$35.37
|
-$143.67K
|
|
SEC
|
Valamehr Bahram
|
Chief R&D Officer
|
|
-25K
|
$31.07
|
-$776.75K
|
|
SEC
|
Chu Yu-Waye
|
Senior VP Clinical Development
|
|
-4K
|
$48.51
|
-$192.34K
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-1.8K
|
$48.45
|
-$85.76K
|
|
SEC
|
TAHL CINDY
|
General Counsel and Secretary
|
|
-5.4K
|
$48.53
|
-$262.98K
|
|
SEC
|
Valamehr Bahram
|
Chief R&D Officer
|
|
-4.6K
|
$48.50
|
-$221.65K
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
-15K
|
$48.68
|
-$709.07K
|
|
SEC
|
TAHL CINDY
|
General Counsel and Secretary
|
|
-7.7K
|
$46.43
|
-$359.28K
|
|
SEC
|
Valamehr Bahram
|
Chief R&D Officer
|
|
-5.6K
|
$46.38
|
-$259.54K
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
-34K
|
$46.86
|
-$1.60M
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-1.5K
|
$48.38
|
-$74.51K
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
+86K
|
$9.01
|
+$779.14K
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
-20K
|
$54.27
|
-$1.09M
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-2.1K
|
$49.81
|
-$106.34K
|
|
SEC
|
Dulac Edward J III
|
Chief Financial Officer
|
|
-3.5K
|
$88.26
|
-$306.62K
|
|
SEC
|
Chu Yu-Waye
|
Senior VP Clinical Development
|
|
-3.3K
|
$83.30
|
-$272.81K
|
|
SEC
|
Valamehr Bahram
|
Chief Development Officer
|
|
-50K
|
$47.63
|
-$2.38M
|
|
SEC
|
Shoemaker Daniel D
|
Chief Scientific Officer
|
|
-25K
|
$81.74
|
-$2.04M
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
+43K
|
$38.48
|
+$1.66M
|
|
SEC
|
Shoemaker Daniel D
|
Chief Scientific Officer
|
|
-9.5K
|
$114.95
|
-$1.09M
|
|
SEC
|
TAHL CINDY
|
General Counsel and Secretary
|
|
-9.5K
|
$114.94
|
-$1.09M
|
|
SEC
|
Valamehr Bahram
|
Chief Development Officer
|
|
-9.5K
|
$114.95
|
-$1.09M
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
-69K
|
$116.33
|
-$8.07M
|
|
SEC
|
Green Jeremy
|
N/A
|
|
+327K
|
$85.50
|
+$28.00M
|
|
SEC
|
Shoemaker Daniel D
|
Chief Scientific Officer
|
|
-25K
|
$51.83
|
-$1.30M
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
-60K
|
$51.87
|
-$3.11M
|
|
SEC
|
TAHL CINDY
|
General Counsel and Secretary
|
|
-71K
|
$50.47
|
-$3.57M
|
|
SEC
|
Shoemaker Daniel D
|
Chief Scientific Officer
|
|
-25K
|
$36.30
|
-$907.50K
|
|
SEC
|
Green Jeremy
|
N/A
|
|
+1.4M
|
$28.31
|
+$40.00M
|
|
SEC
|
RASTETTER WILLIAM H
|
N/A
|
|
+28K
|
$1.37
|
+$38.99K
|
|
SEC
|
Valamehr Bahram
|
Chief Development Officer
|
|
+1.2K
|
$1.69
|
+$1.95K
|
|
SEC
|
Shoemaker Daniel D
|
Chief Scientific Officer
|
|
+19K
|
$3.84
|
+$74.11K
|
|
SEC
|
TAHL CINDY
|
General Counsel and Secretary
|
|
+19K
|
$3.85
|
+$74.31K
|
|
SEC
|
Valamehr Bahram
|
Chief Development Officer
|
|
+19K
|
$3.84
|
+$74.11K
|
|
SEC
|
Shoemaker Daniel D
|
Chief Scientific Officer
|
|
-12K
|
$14.29
|
-$168.62K
|
|
SEC
|
TAHL CINDY
|
General Counsel and Secretary
|
|
-10K
|
$14.24
|
-$145.25K
|
|
SEC
|
Valamehr Bahram
|
Chief Development Officer
|
|
-6.2K
|
$14.18
|
-$87.92K
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
-21K
|
$14.44
|
-$303.49K
|
|
SEC
|
Green Jeremy
|
N/A
|
|
+857K
|
$17.50
|
+$15.00M
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-62K
|
$22.53
|
-$1.40M
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-118K
|
$22.51
|
-$2.66M
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-82K
|
$22.51
|
-$1.84M
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-71K
|
$22.52
|
-$1.60M
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
-20K
|
$17.61
|
-$352.20K
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-53K
|
$14.16
|
-$750.72K
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-98K
|
$14.16
|
-$1.38M
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-70K
|
$13.78
|
-$964.60K
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-90K
|
$14.14
|
-$1.27M
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-39K
|
$16.28
|
-$642.78K
|
|
SEC
|
TAHL CINDY
|
General Counsel and Secretary
|
|
+45K
|
$4.81
|
+$216.45K
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-33K
|
$12.25
|
-$410.06K
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-91K
|
$13.40
|
-$1.22M
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-18K
|
$16.67
|
-$296.53K
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-425K
|
$16.78
|
-$7.13M
|
|
SEC
|
Nashat Amir
|
N/A
|
|
-83K
|
$16.71
|
-$1.38M
|
|
SEC
|
Green Jeremy
|
N/A
|
|
+3.7M
|
$13.50
|
+$50.00M
|
|
SEC
|
ABBOT STEWART
|
Chief Development Officer
|
|
+21K
|
$6.62
|
+$139.38K
|
|
SEC
|
Shoemaker Daniel D
|
Chief Scientific Officer
|
|
-13K
|
$3.87
|
-$51.18K
|
|
SEC
|
TAHL CINDY
|
General Counsel and Secretary
|
|
-8.1K
|
$3.85
|
-$31.15K
|
|
SEC
|
Wolchko J Scott
|
President and CEO
|
|
-17K
|
$3.88
|
-$66.61K
|
|
SEC
|
Coughlin Timothy P
|
N/A
|
|
+56K
|
$2.66
|
+$150.00K
|
|
SEC
|
RASTETTER WILLIAM H
|
N/A
|
|
+376K
|
$2.66
|
+$1.00M
|
|
SEC
|
Storgard Chris
|
Chief Medical Officer
|
|
+38K
|
$2.66
|
+$100.00K
|
|
SEC
|
Flynn Peter D
|
See remarks
|
|
-6.5K
|
$7.00
|
-$45.42K
|
|
SEC
|
Flynn Peter D
|
See remarks
|
|
-3.3K
|
$7.00
|
-$23.14K
|
|
SEC
|
Flynn Peter D
|
See remarks
|
|
-9.8K
|
$7.07
|
-$69.24K
|
|
SEC
|
Flynn Peter D
|
See remarks
|
|
-5.9K
|
$8.00
|
-$47.11K
|
|
SEC
|
Weyer Christian
|
See remarks
|
|
-10K
|
$9.02
|
-$90.20K
|
|
SEC
|
Flynn Peter D
|
See remarks
|
|
-4K
|
$9.79
|
-$39.53K
|
|
SEC
|
Wolchko J Scott
|
See remarks
|
|
-20K
|
$9.64
|
-$192.80K
|
|
SEC
|
Shoemaker Daniel D
|
Chief Technology Officer
|
|
-8.7K
|
$9.86
|
-$85.32K
|
|
SEC
|
BYBEE CLINTON
|
N/A
|
|
+833K
|
$6.00
|
+$5.00M
|
|
SEC
|
MENDLEIN JOHN
|
N/A
|
|
+17K
|
$6.00
|
+$100.00K
|
|
SEC
|
Nashat Amir
|
N/A
|
|
+833K
|
$6.00
|
+$5.00M
|
|
SEC
|
NELSEN ROBERT
|
N/A
|
|
+833K
|
$6.00
|
+$5.00M
|
|
SEC
|
Polaris Venture Partners Special Founders' Fund V, L.P.
|
N/A
|
|
+833K
|
$6.00
|
+$5.00M
|
|
SEC
|
RASTETTER WILLIAM H
|
N/A
|
|
+83K
|
$6.00
|
+$500.00K
|
|
SEC
|
VEF Management V, LLC
|
N/A
|
|
+833K
|
$6.00
|
+$5.00M
|
|